(0.06%) 5 109.75 points
(-0.16%) 38 664 points
(0.50%) 17 694 points
(-0.35%) $83.07
(-3.37%) $1.751
(-0.32%) $2 334.70
(-0.08%) $27.34
(-1.02%) $913.40
(0.16%) $0.936
(0.82%) $10.99
(0.10%) $0.804
(-0.77%) $92.48
Live Chart Being Loaded With Signals
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China...
Stats | |
---|---|
Today's Volume | 128 000 |
Average Volume | 88 593.00 |
Market Cap | 508.22M |
EPS | HKD0 ( 2023-08-30 ) |
Last Dividend | HKD0.00980 ( 2023-05-31 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 25.00 |
ATR14 | HKD0 (0.00%) |
Sinco Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sinco Pharmaceuticals Financials
Annual | 2022 |
Revenue: | HKD2.27B |
Gross Profit: | HKD305.87M (13.47 %) |
EPS: | HKD0.0342 |
Q2 | 2023 |
Revenue: | HKD1.09B |
Gross Profit: | HKD152.55M (13.99 %) |
EPS: | HKD0.00960 |
Q4 | 2022 |
Revenue: | HKD1.14B |
Gross Profit: | HKD113.67M (9.96 %) |
EPS: | HKD0.00370 |
Q2 | 2022 |
Revenue: | HKD1.13B |
Gross Profit: | HKD192.20M (17.01 %) |
EPS: | HKD0.0305 |
Financial Reports:
No articles found.
Sinco Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.00980 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00330 | 2016-09-09 |
Last Dividend | HKD0.00980 | 2023-05-31 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | HKD0.0131 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.37 | -- |
Div. Sustainability Score | 9.62 | |
Div.Growth Potential Score | 4.73 | |
Div. Directional Score | 7.18 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3382.HK | Ex Dividend Junior | 2023-06-19 | Annually | 0 | 0.00% | |
1596.HK | Ex Dividend Junior | 2023-05-31 | Annually | 0 | 0.00% | |
0635.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
9918.HK | Ex Dividend Junior | 2023-06-06 | Annually | 0 | 0.00% | |
2177.HK | Ex Dividend Junior | 2023-09-12 | Sporadic | 0 | 0.00% | |
1177.HK | Ex Dividend Knight | 2023-10-04 | Semi-Annually | 0 | 0.00% | |
0255.HK | Ex Dividend Junior | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
3877.HK | Ex Dividend Junior | 2023-06-28 | Semi-Annually | 0 | 0.00% | |
1752.HK | Ex Dividend Junior | 2023-11-30 | Sporadic | 0 | 0.00% | |
0788.HK | Ex Dividend Junior | 2023-05-16 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0122 | 1.500 | 9.76 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0165 | 1.200 | 9.45 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0449 | 1.500 | -0.612 | -0.919 | [0.1 - 1] |
payoutRatioTTM | 0.668 | -1.000 | 3.32 | -3.32 | [0 - 1] |
currentRatioTTM | 1.183 | 0.800 | 9.08 | 7.27 | [1 - 3] |
quickRatioTTM | 0.818 | 0.800 | 9.90 | 7.92 | [0.8 - 2.5] |
cashRatioTTM | 0.517 | 1.500 | 8.24 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.125 | -1.500 | 7.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.203 | 2.00 | 9.93 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.180 | 2.00 | 9.91 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.339 | -1.500 | 8.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.119 | 1.000 | -1.345 | -1.345 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0343 | 1.000 | -1.314 | -1.314 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.01 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 1.359 | 0.800 | 4.27 | 3.42 | [0.5 - 2] |
Total Score | 9.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.30 | 1.000 | 8.35 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0449 | 2.50 | -0.394 | -0.919 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.180 | 2.00 | 9.94 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.24 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.203 | 2.00 | 9.93 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.668 | 1.500 | 3.32 | -3.32 | [0 - 1] |
pegRatioTTM | 0.208 | 1.500 | -1.949 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.185 | 1.000 | 7.87 | 0 | [0.1 - 0.5] |
Total Score | 4.73 |
Sinco Pharmaceuticals
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, including alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company engages in the sale of pharmaceutical products; and provides warehouse facilities for pharmaceutical products; and offers international trade services, as well as provides consultation services for medical and biological technology. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators